Fate Therapeutics (NASDAQ:FATE – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Fate Therapeutics to related businesses based on the strength of its risk, institutional ownership, profitability, analyst recommendations, dividends, earnings and valuation.
Risk & Volatility
Fate Therapeutics has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Comparatively, Fate Therapeutics’ peers have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.
Earnings and Valuation
This table compares Fate Therapeutics and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fate Therapeutics | $6.49 million | -$136.32 million | -1.78 |
| Fate Therapeutics Competitors | $728.25 million | $12.25 million | -15.19 |
Fate Therapeutics’ peers have higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a breakdown of recent ratings for Fate Therapeutics and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fate Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
| Fate Therapeutics Competitors | 9838 | 15122 | 45436 | 1587 | 2.54 |
Fate Therapeutics presently has a consensus target price of $5.80, suggesting a potential upside of 216.08%. As a group, “Biotechnology” companies have a potential upside of 102.61%. Given Fate Therapeutics’ higher possible upside, equities analysts clearly believe Fate Therapeutics is more favorable than its peers.
Institutional and Insider Ownership
97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 4.7% of Fate Therapeutics shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Fate Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fate Therapeutics | -1,941.09% | -69.09% | -43.21% |
| Fate Therapeutics Competitors | -12,357.18% | -197.96% | -30.56% |
Summary
Fate Therapeutics beats its peers on 7 of the 13 factors compared.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
